1.06
1.06 (0%)
As of Apr 17, 2025
Inflarx N.V. [IFRX]
Source:
Company Overview
Inflarx N.v. is a biopharmaceutical company pioneeringanti-inflammatory therapeutics by targeting the complement system. We do this by applying our proprietary technologies to discover, developand commercialize first-in-class, highly potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR.
| Country | Germany |
| Headquarters | jena, germany |
| Phone Number | 49 (3641) 508 180 |
| Industry | manufacturing |
| CEO | Niels Riedemann |
| Website | www.inflarx.de |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $-53 |
| Net Income | $-46.1 |
| Net Cash | $4.2 |
Profit Ratios
| Gross Margin | $-3.2 |
| Operating Margin | -31,973.7 |
| Profit as % of Revenues | 6.8% |
| Profit as % of Assets | -47% |
| Profit as % of Stockholder Equity | -75% |
Management Effectiveness
| Return on Equity | -75% |
| Return on Assets | -60.6% |
| Turnover Ratio | 0.2% |
| EBITA | $-53 |
Balance Sheet and Cash Flow Measures
| Total Assets | $76 |
| Total Liabilities | $14.6 |
| Operating Cash Flow | $-48.6 |
| Investing Cash Flow | $52.4 |
| Financing Cash Flow | $0.4 |
